ReviewImmunity, inflammation and disease2026
TCM-Guided Targeted Therapies Against NLRP3 Inflammasome in NAFLD.
Review in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder driven by inflammation, in which the NLRP3 inflammasome plays a central role. Current targeted inhibitors face challenges in patient stratification and long-term safety.
methodsA narrative literature review was conducted using PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), and Google Scholar from database inception to February 2026. Search terms included combinations of "non-alcoholic fatty liver disease", "NAFLD", "NASH", "NLRP3 inflammasome", "traditional Chinese medicine", "TCM", "herbal medicine", "syndrome differentiation", and "precision medicine". Peer-reviewed original articles, systematic reviews, and clinical studies addressing NLRP3 in NAFLD or TCM-based interventions targeting this pathway were prioritized.
resultsTCM syndrome patterns (e.g., damp-heat, phlegm-damp) correlate with distinct NLRP3 activation states and inflammatory phenotypes. Herbal compounds such as berberine and curcumin, as well as classical TCM formulae, exert multi-target effects by suppressing NLRP3 inflammasome assembly, enhancing antioxidant defenses, and modulating the gut-liver axis. Based on this evidence, we propose an integrative "TCM Syndrome-NLRP3 Molecular Endotype-Precision Targeted Therapy" model that links specific TCM syndromes to canonical, non-canonical, or sustained NLRP3 activation, thereby providing hypothesis-driven strategies for personalized intervention. DISCUSSION: This integrative framework bridges TCM holistic principles with modern inflammasome biology. It provides a theoretical basis for personalized, biomarker-driven NAFLD therapies, highlighting the synergy between traditional medicine and precision hepatology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.